Evidence map›Paper›PMID 27000123›Full record

ReviewJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2016

Drug Abuse, HIV, and HCV in Asian Countries.

Yih-Ing Hser, Di Liang, Yu-Ching Lan, Balasingam Kasinather Vicknasingam, Amit Chakrabarti

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 4 countries.

Yih-Ing HserUniversity of California, Los Angeles, Los Angeles, CA, USA. yhser@ucla.edu.
Di LiangUniversity of California, Los Angeles, Los Angeles, CA, USA.
Yu-Ching LanChina Medical University, Taichung City, Taiwan.
Balasingam Kasinather VicknasingamCentre for Drug Research, Universiti Sains Malaysia, Gelugor, Penang, Malaysia.
Amit ChakrabartiRegional Occupational Health Centre (ROHC), Eastern, National Institute of Occupational Health, Ahmedabad, Gujarat, India.
University of California, Los Angeles · USChina Medical University · TWNational Institute of Occupational Health · INUniversiti Sains Malaysia · MY

Funding

STATISTICAL SUPPORT/DATA MANAGEMENT COREP30DA016383 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HSER, YIH-ING · 2005 to 2015
$8.6M
Conference Series to Promote Global Health...R13DA035084 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HSER, YIH-ING · 2013 to 2017
$143k
NIDA NIH HHS P30 DA016383NIDA NIH HHS R13 DA035084
6 · The paper itself

Abstract

Drug abuse and co-occurring infections are associated with significant morbidity and mortality. Asian countries are particularly vulnerable to the deleterious consequences of these risks/problems, as they have some of the highest rates of these diseases. This review describes drug abuse, HIV, and hepatitis C (HCV) in Asian countries. The most commonly used illicit drugs include opioids, amphetamine-type stimulants (ATS), cannabis, and ketamine. Among people who inject drugs, HIV rates range from 6.3 % in China to 19 % in Malaysia, and HCV ranges from 41 % in India and Taiwan to 74 % in Vietnam. In the face of the HIV epidemics, drug policies in these countries are slowly changing from the traditional punitive approach (e.g., incarcerating drug users or requiring registration as a drug user) to embrace public health approaches, including, for example, community-based treatment options as well as harm reduction approaches to reduce needle sharing and thus HIV transmission. HIV and HCV molecular epidemiology indicates limited geographic diffusion. While the HIV prevalence is declining in all five countries, use of new drugs (e.g., ATS, ketamine) continues to increase, as well as high-risk sexual behaviors associated with drug use-increasing the risk of sexual transmission of HIV, particularly among men who have sex with men. Screening, early intervention, and continued scaling up of therapeutic options (drug treatment and recovery support, ART, long-term HIV and HCV care for drug users) are critical for effective control or continued reduction of drug abuse and co-infections.

Indexed as

AsiaCoinfectionHepatitis CHIV InfectionsHumansSubstance-Related DisordersAsiaChinaDrug abuseHCVHIVIndiaMalaysiaTaiwanVietnam

Identifiers

PMID27000123
OpenAlexW2301532486

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.